CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-05). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2294 · Search date 2026-08-05 · Methodology v0.6

Bedtime versus morning-fasting levothyroxine,
does it really help with Lower thyroid-stimulating hormone versus dosing 30 minutes before breakfast?

30-Second Summary
C
Evidence Grade C · 59 · Safety caution
Fasting bedtime dosing lowered TSH versus dosing 30 minutes before breakfast, but did not improve symptoms
Levothyroxine has a narrow therapeutic range and interacts with food, iron, calcium, and several medicines. After changing timing, keep the routine consistent and review thyroid tests with a clinician after about six to eight weeks.
What the
research shows
The grade is C with 59 points. In a double-blind crossover trial, 105 adults enrolled and 90 were analyzed. Each schedule lasted 12 weeks and participants switched directly without a separate washout. Bedtime dosing lowered thyroid-stimulating hormone by 1.25 mIU/L versus dosing 30 minutes before breakfast, 95% CI 0.60 to 1.89. Laboratory values changed, but quality of life, fatigue, and symptoms did not.
What the
ads claim
Verdict 923 is A with 86 points for levothyroxine correcting overt hypothyroidism, while verdict 1779 is F with 8 points for symptom improvement in subclinical hypothyroidism. This is the separate dosing-time question of bedtime fasting versus morning fasting.
*

Useful facts when choosing a product

  • Each crossover schedule lasted 12 weeks, with no separate washout before switching.
  • Ninety of 105 enrolled participants provided the analyzed completer data.
  • Thyroid-stimulating hormone is a surrogate; symptoms, fatigue, and quality of life did not improve.
  • No financial conflicts were reported, but the funding source was not confirmed.
Gap Measurement · Verdict 2294 · C 59
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Bolk and colleagues enrolled 105 adults with primary hypothyroidism on a stable dose for at least six months. Participants took one morning and one bedtime capsule, one containing levothyroxine and the other placebo, then switched contents after three months for another three months. Ninety completers were analyzed. There was no separate washout; the paper tested first-order carryover and did not detect it. Bedtime direct effects were TSH -1.25 mIU/L, 95% CI -1.89 to -0.60, free T4 +0.07 ng/dL, 0.02 to 0.13, and total T3 +6.5 ng/dL, 0.9 to 12.1. Quality of life, fatigue, and symptoms did not differ. The financial-disclosure section reported none. The funding source could not be confirmed.

02

Why this is classified as C (59)

A small single crossover trial found a medium-sized TSH difference, but the outcome was surrogate-only, giving C with 59 points.

Counterpoint. Food, iron, and calcium near bedtime can change absorption. Timing should not be changed without a consistent routine and follow-up testing.

Rejudgment record. Cross-check applied — Crossover design, 12-week periods, no separate washout, 105 enrolled versus 90 completers, the direct TSH effect and approximate standardized magnitude, null symptom outcomes, and unconfirmed funding were applied

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Fasting bedtime dosing lowers TSH versus dosing 30 minutes before breakfastCThe direct effect was -1.25 mIU/L in 90 completers.
Bedtime dosing improves fatigue or symptomsDQuality-of-life, fatigue, and symptom questionnaires did not differ.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Randomized double-blind placebo-capsule crossover trial90Nothing was reported in the financial-disclosure section; the funding source could not be confirmedTSH, free T4, and total T3 after each 12-week period; symptoms and quality of life were secondaryBedtime dosing lowered TSH by 1.25 mIU/L, 95% CI 0.60 to 1.89; quality of life, fatigue, and symptoms did not differ.Pivotal small surrogate-endpoint crossover trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-05).

Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JGP, Berghout A. Effects of Evening vs Morning Levothyroxine Intake: A Randomized Double-blind Crossover Trial. Arch Intern Med. 2010;170(22):1996-2003. PMID: 21149757. DOI: 10.1001/archinternmed.2010.436.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-05 · Corrections: none

Cite this verdict

Bedtime versus morning-fasting levothyroxine x thyroid-stimulating hormone Evidence Grade C card
[Chamgap] Bedtime versus morning-fasting levothyroxine x thyroid-stimulating hormone — Evidence Grade C·59. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/levothyroxine-bedtime-vs-morning-fasting-tsh/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.